Zealand hands off dis­ap­point­ing di­a­betes rev­enue from Sanofi in ex­change for a $205M in­jec­tion to back a new pipeline

Dan­ish biotech Zealand Phar­ma is cash­ing in its roy­al­ty chips on its lack­lus­ter di­a­betes drugs. The com­pa­ny, which has switched fo­cus to its rare dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.